Published

2018: A watershed year for psychedelic science

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Drug Science Policy and Law
Date: 2019-01-01
Source: OpenAlex
DOI: 10.1177/2050324519872284
PubMed: Unavailable

Authors

Jacob S. Aday Christopher C. Davoli Emily K. Bloesch

Watch author

Derived topics and classifications

psilocybin Depression Pharmacology Treatment-Resistant Depression Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

2018: A watershed year for psychedelic science2019-01-01

Related papers

A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic CancerClinicalTrials.gov · 2025-11-05 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and DepressionClinicalTrials.gov · 2026-07-31 Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)ClinicalTrials.gov · 2026-05-14 A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic CancerClinicalTrials.gov · 2025-10-14 The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)ClinicalTrials.gov · 2025-07-23 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring OpioidsClinicalTrials.gov · 2026-08-12